Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors

Aadi Bioscience, a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, has announced the appointment of Mohammad Hirmand to its Board of Directors. Dr. Hirmand has more than 20 years of biotechnology clinical development experience, and recently served as executive vice president and chief medical officer for Turning Point Therapeutics, which was acquired by Bristol Myers Squibb (BMS) for $4.1 billion in August 2022.

“We welcome Mohammad to our Board at an exciting time for Aadi, as we advance the development of FYARRO for unmet clinical needs beyond our approved indication of PEComa. Mohammad is a world-class clinical development leader in oncology and will be a great complement to our board and partner with our highly experienced team,” said Caley Castelein, M.D., Aadi Board Chairman. “Mohammad has been instrumental in the development of Medivation’s Xtandi and Welireg (belzutifan), when at Peloton Therapeutics. Most recently, he led the development of Turning Point Therapeutics’ clinical pipeline including the tyrosine kinase inhibitor repotrectinib prior to the company’s acquisition by BMS. We look forward to working together and to his contributions as we drive toward continued growth and clinical expansion here at Aadi.”

Dr. Hirmand is a co-founder of Avenzo Therapeutics, a privately held oncology company, and serves as its executive vice president and chief medical officer. Previously, Dr. Hirmand served as executive vice president and chief medical officer of Turning Point Therapeutics, a publicly traded precision oncology company, where he was responsible for all development functions from December 2019 until its acquisition by BMS in August 2022.

“I am excited to join Aadi’s Board of Directors in their mission to unlock the potential of nab-sirolimus in addressing mTOR-driven diseases,” said Dr. Hirmand. “Aadi’s PRECISION-1 trial studying nab-sirolimus in solid tumors with TSC1 and TSC2 inactivating alterations represents an exciting potential advancement in targeted oncology. I look forward to working with the outstanding Aadi team to transform the lives of patients living with cancer.”

Dr. Hirmand also served as chief medical officer of Peloton Therapeutics from 2017 until its acquisition by Merck & Co., Inc. in 2019. Dr. Hirmand served in various roles at Medivation, Inc., a publicly traded biotechnology company, from 2007 to 2017, including most recently as its chief medical officer, through its acquisition by Pfizer Inc. He has also held clinical development roles of increasing responsibility at Nuvelo, Inc. (now ARCA Biopharma), SuperGen, Inc. (now Astex Pharmaceuticals, Inc.), Tularik, Inc. (now part of Amgen), and Theravance Biopharma, Inc. Dr. Hirmand received his M.D. from Harvard Medical School and his B.A. in Biological Sciences and Economics from Cornell University.